Surveyed U.S. Cardiologists and MCOs Indicate That Reduced Incidence of Mortality is the Greatest Unmet Need in Post-Myocardial

  Surveyed U.S. Cardiologists and MCOs Indicate That Reduced Incidence of
  Mortality is the Greatest Unmet Need in Post-Myocardial Infarction; Xarelto
  Has Demonstrated Potential to Significantly Fulfill This Unmet Need

   An Oral Antiplatelet Agent With a Slightly Lower Rate of Major Bleeding,
Comparable Efficacy and Priced 20 Percent Less Than Clopidogrel, Could Earn a
50 Percent Patient Share in the U.S., According to a New Report from Decision
                                  Resources

Business Wire

BURLINGTON, Mass. -- June 14, 2012

Decision Resources, one of the world’s leading research and advisory firms for
pharmaceutical and healthcare issues, finds that, according to insights from
surveyed U.S. cardiologists and managed care organization (MCO) pharmacy
directors, the reduced incidence of mortality is the greatest unmet need in
post-myocardial infarction.

“Despite the declining rate of deaths due to myocardial infarction and despite
the emergence of novel antiplatelet agents and optimal statin therapy, the
incidence of mortality remains the attribute that most influences surveyed
cardiologists’ prescribing decisions in post-myocardial infarction,” said
Decision Resources Analyst Conor Walsh, Ph.D. “According to clinical data and
thought leaders we interviewed, Bayer/Janssen’s Xarelto has demonstrated the
potential to significantly fulfill this unmet need.”

Clinical data and interviewed thought leaders also indicate that the regimen
of aspirin (Bayer’s Aspirin, generics) plus ticagrelor (AstraZeneca’s
Brilinta/Brilique) plus atorvastatin (Pfizer’s Lipitor, generics) plus
metoprolol (AstraZeneca’s Toprol, Novartis’s Lopressor, generics) plus
ramipril (Pfizer’s Altace, Sanofi’s Triatec, AstraZeneca’s Vesdil, generics)
has advantages on the attribute of reduced incidence of mortality over the
sales-leading regimen for post-myocardial infarction—aspirin plus clopidogrel
(Bristol-Myers Squibb/Sanofi’s Plavix/Iscover, generics) plus atorvastatin
plus metoprolol plus ramipril.

The DecisionBase 2012 report entitled Post-Myocardial Infarction: Substantial
Opportunity Exists for Novel Antithrombotic Agents That Reduce Bleeding More
than Clopidogrel alsofinds that major bleeding continues to be a significant
factor in the prescribing decisions of surveyed cardiologists. According to
surveyed cardiologists, an oral antiplatelet agent with a slightly lower rate
of non-CABG-related TIMI (thrombolysis in myocardial infarction) major
bleeding, comparable efficacy and priced at a 20 percent discount compared to
clopidogrel, could earn the same patient share (50 percent) in the U.S. as a
substantially more efficacious drug that is associated with notably lower
bleeding rates, but is priced at a 20 percent premium to clopidogrel.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be
       trademarks or registered trademarks of their respective holders.

Contact:

Decision Resources
Christopher Comfort, 781-993-2597
ccomfort@dresources.com
 
Press spacebar to pause and continue. Press esc to stop.